News
Lifecycle Management Strategies: Reformulations – Success hinges on delivering significant improvement in disease outcome
Reformulation has been one of the dominant and successful lifecycle management strategies in the past but changes in the healthcare environment are hampering their success. However, reformulated products can still achieve commercial success provided they satisfy key stakeholder needs by providing significant improvements in disease outcomes.
Features and benefits
- Analysis of success drivers and resistors of reformulation as a lifecycle management strategy
- Discussion of how reformulation can satisfy key stakeholder needs.
- Case study of recent successful and unsuccessful reformulations.
Highlights
In the past, reformulation was one of the most popular and successful lifecycle management strategies, with most companies launching reformulated versions of their first generation products shortly before patent expiry, and subsequently switching patients onto these in order to drive franchise sales.
However, with cost containment taking center stage in most markets, payers have introduced measures to restrict the use of reformulated products unless significant benefit in terms of disease outcome and compliance can be demonstrated.
It is critical that reformulations deliver tangible improvements in disease outcomes, with head-to-head trials against first generation versions necessary to demonstrate superiority key to successful uptake among both payers and physicians
Your key questions answered
- How can reformulation drive or maintain franchise sales?
- How have changes in the healthcare environment in the last few years made it more difficult for reformulations to achieve commercial success?
- Can reformulations still be commercially successful and how?
Get your copy of this report @ http://www.reportsnreports.com/reports/182231-lifecycle-management-strategies-reformulations-success-hinges-on-delivering-significant-improvement-in-disease-outcome.html
Table of Contents
EXECUTIVE SUMMARY
Introduction
Strategic scoping and focus
Key findings
Related reports
REFORMULATION LIFECYCLE MANAGEMENT STRATEGY OVERVIEW
What is reformulation?
Drivers and resistors of reformulation
Regulatory issues to be considered when reformulating
Market withdrawal of the original product is an ineffectual tactic for delaying generics
Only robust reformulation patents can protect line extensions
Why and when reformulate?
Reformulated product must better satisfy key stakeholder needs
Case study summary
REFORMULATION CASE STUDIES
Astepro (once-daily azelastine; Meda Pharma): head-to-head trials lead to a successful switch
Lesson
Background
Impact
Lupron (leuprorelin; Abbott Laboratories): broad portfolio of formulations and brand loyalty maintain sales despite patent expiry
Lesson
Background
Impact
Risperdal/Risperdal Consta (risperidone) and Invega/Invega Sustenna (paliperidone): success hinges on providing significant improvement in outcome
Lesson
Background
Impact
Dovonex (calcipotriol; Leo Pharma): original product withdrawal encourages switching but damages company reputation
Lesson
Background
Impact
Zosyn (piperacillin/tazobactam; Pfizer/Taisho Pharmaceuticals): withdrawal of original formulation delays generic entry
Lesson
Background
Impact
BIBLIOGRAPHY
Publications and online articles
Datamonitor reports and products
List of Tables
Table: Reformulation case studies summary
List of Figures
Figure: Success drivers and resistors of reformulation as a lifecycle management strategy
Figure: Reformulation are developed with different aims depending on the stage of the lifecycle when they are used
Figure: Targeting key stakeholders’ needs increases chances of a successful reformulation strategy
Figure: Astelin/Astepro sales in the US ($m), 2011–19
Figure: Global sales of the Lupron franchise and Eligard ($m), 2002–16
Figure: Risperdal and Risperdal Consta global sales ($m), 2002–16
Figure: Invega and Invega Sustenna global sales ($m), 2002–16
Figure: Johnson & Johnson’s antipsychotic franchise global sales (Risperdal, Risperdal Consta, Invega and Invega Sustenna) ($m), 2002–16
Figure: Dovonex US sales ($m), 2006–10
Figure: Zosyn sales in the US ($m), 2005–16
More News
Organic Light Emitting Diodes (OLEDs): Technologies and Global Markets
Released On: 9/3/2012
Views: 3141
2012 China Synthesis Polypeptide Drug Industry Market Research Report
Released On: 8/31/2012
Views: 3869
Global and China Polyurethane Industry Chain Report, 2011-2012
Released On: 8/27/2012
Views: 2154
IP Multimedia Subsystem (IMS) Solutions and Market Opportunities
Released On: 8/23/2012
Views: 3012
Personal Accident and Health Insurance in Hong Kong, Key Trends and Opportunities to 2016
Released On: 8/23/2012
Views: 2031
Graphene: Technologies, Applications and Markets: ReportsnReports
Released On: 8/21/2012
Views: 2725
Supraventricular Tachycardia (SVT) Therapeutics - Pipeline Assessment and Market Forecasts to 2019
Released On: 8/16/2012
Views: 3366
2012 Market Research Report on China Reversing Camera System Industry
Released On: 8/16/2012
Views: 1984
2012 Market Research Report on China Child Safety Seat Industry
Released On: 8/16/2012
Views: 4232
ReportsnReports: Agricultural Biotechnology: Emerging Technologies and Global Markets
Released On: 8/14/2012
Views: 2110
Clothing and footwear retail market in Poland 2012: ReportsnReports
Released On: 8/14/2012
Views: 1813
